Skip to main content

Merck Serono, Caprotec Collaborate on Protein Research

NEW YORK (GenomeWeb News) – Caprotec Bioanalytics said today that it will collaborate with a division of Merck KGaA to identify protein and drug interactions using its mass spectrometry technology.
 
Under the agreement, Caprotec will use its Capture Compound Mass Spectrometry technology for a research project for Merck Serono. Berlin-based Caprotec will be paid research fees and milestone payments for product development, it said.
 
The firm’s CCMS technology consists of small, tri-functional molecules that allow researchers to isolate proteins directly from biological samples that may then be isolated and characterized. The technology can be used in proteomics, drug development, and biomarker research, the company said.
 
Financial terms of the agreement were not released.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.